Immediate Impact

2 by Nobel laureates 3 from Science/Nature 70 standout
Sub-graph 1 of 23

Citing Papers

Naturally occurring T cell mutations enhance engineered T cell therapies
2024 StandoutNature
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
2024 Standout
3 intermediate papers

Works of Barbara Formisano being referenced

Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?
2006
Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-α2b in metastatic melanoma
2006

Author Peers

Author Last Decade Papers Cites
Barbara Formisano 443 290 192 21 524
Boris G. Naraev 372 293 219 22 506
Tatianna Larman 262 107 86 23 583
Yasushi Otani 374 66 133 19 593
Kvols Lk 419 337 242 22 572
W. Victoria Lai 523 339 87 23 622
Antonette E. Leon 251 147 73 24 637
Itsuro Hayashi 457 194 29 19 612
Monica Verrico 243 142 36 30 463
Janet Li 197 263 101 20 459
Marianna Macerelli 276 133 198 27 599

All Works

Loading papers...

Rankless by CCL
2026